Loading clinical trials...

EHR-integrated rUTI Texting Platform | Clinical Trials | Clareo Health

COMPLETEDNA

EHR-integrated rUTI Texting Platform

An EHR-integrated Texting Platform to Promote Self-management in Women With Recurrent Urinary Tract Infections

NCT06035601•University of Pennsylvania

Summary

The goal of this clinical trial is to compare a texting platform to usual care for managing recurrent urinary tract infections (UTI). The main question it aims to answer is: • can a texting platform that integrates symptom triage and prevention education reduce the rate of unnecessary antibiotics for recurrent UTIs as compared to usual care? Participants enrolled onto the texting platform will: • receive evidence-based clinical guidance for the management of symptoms of UTI and receive educational videos on how to prevent UTIs. An important secondary outcome is to determine if the texting platform improves self-efficacy for the management of recurrent UTI.

Eligibility

Age

18 - 100 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•1. Provision of signed and dated informed consent form
•2. Stated willingness to comply with all study procedures and availability for the duration of the study
•3. Females who currently meet the criteria for recurrent UTIs
•4. Age 18 years or older
•5. Owns a mobile device with text messaging capability
•6. Ability to read and write English
•7. Currently receiving care from a provider in Penn Urogynecology or Penn Urology

Exclusion Criteria

•1. History of known multidrug resistant UTIs
•2. History of interstitial cystitis/bladder pain syndrome or current diagnosis of chronic pelvic pain
•3. On continuous suppressive antibiotics currently
•4. Currently pregnant or within 6 weeks of pregnancy
•5. Transplant patient on immunosuppressive medication currently
•6. Practice of chronic self-catheterization

Locations (1)

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

March 7, 2024

Primary Completion Date

May 31, 2025

Completion Date

May 31, 2025

Last Updated

August 17, 2025

Enrollment

104

ACTUAL participants

Conditions

Recurrent Urinary Tract Infection

Interventions

EHR-integrated texting platform (Urotrust)

DEVICE

Usual care

OTHER

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

NCT06353269

Recurrent Urinary Tract InfectionHypoestrogenism

View study

ACTIVE_NOT_RECRUITINGPHASE4

Preference of Women With Recurrent Urinary Tract Infection for Vaginal Estradiol Tablet vs Cream

NCT05723601

Recurrent Urinary Tract Infection

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 17, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

EHR-integrated rUTI Texting Platform

Inclusion Criteria

Exclusion Criteria

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

Preference of Women With Recurrent Urinary Tract Infection for Vaginal Estradiol Tablet vs Cream

RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women with Recurrent Urinary Tract Infections

Phage Therapy for the Treatment of Urinary Tract Infection

Comparison of Three Different Antibiotic Treatments Against Recurrent Urinary Tract Infections in Catheterized Patients

Pain-perception During Outpatient cystoscopy-a Prospective Controlled Study